FIELD: biotechnology.
SUBSTANCE: following is proposed: anti-CLDN18.2 antibody or its active fragment, method of its detection, polynucleotide encoding the antibody or its active fragment; pharmaceutical composition to treat the tumor expressing CLDN18.2, as well as using the antibody or its active fragment to obtain an anti-tumor medicinal product to treat the tumor expressing CLDN18.2 and a method of treating tumors.
EFFECT: invention makes it possible to obtain an antibody, the ability of which to bind to cell lines and tumor tissue cells is more pronounced than that of the existing IMAB362 antibody, and the antitumor effect of this antibody is also more powerful than that of the existing IMAB362 antibody.
7 cl, 14 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
